NOI to Sole Source AMICUS Apheresis Reagents & Consumables
| Agency: | DEPT OF DEFENSE |
|---|---|
| State: | Federal |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Set Aside: | No Set aside used |
| Posted Date: | Aug 13, 2026 |
| Due Date: | Aug 28, 2026 |
| Solicitation No: | HT941026N0107 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Sources Sought (Original)
- Original Published Date: Aug 13, 2026 10:11 am PDT
- Original Response Date: Aug 28, 2026 10:00 am PDT
- Inactive Policy: 15 days after response date
- Original Inactive Date: Sep 12, 2026
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
-
NAICS Code:
- 325413 - In-Vitro Diagnostic Substance Manufacturing
-
Place of Performance:
USA
Notice of Intent to Sole Source HT941026N0107
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.
The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – West (HCD-W), intends to award a firm-fixed-price purchase order for Drop Shipment of FDA Fenwal Amicus Apheresis Reagents (Manufacturer: Fenwal, Inc.). This procurement supports the operational requirements of Naval Hospital Okinawa, Japan, and is conducted in accordance with Federal Acquisition Regulation (FAR) 12.102(a), this acquisition of commercial products and services is being executed as a sole source, as the Contracting Officer does not have a reasonable expectation that two or more offers will be received.
FENWAL, INC., 3 CORPORATE DR STE 300, LAKE ZURICH, IL 60047-8930, United States
UEI: E9UHXHZCGJV5
CAGE: 4Q7Q2
The North American Industry Classification System (NAICS) code for this requirement is 325413, In-Vitro Diagnostic Substance Manufacturing, which has a business size standard of 1,250 employees. The product service code (PSC) is 6550, In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets.
The objective of this sole source award is to procure Amicus Apheresis reagents for the cell separator for Naval Hospital Okinawa, located at Bldg 960, Tarawa Road, Camp Foster, Okinawa, Japan.
The requested Intecept platelet small volume processing set and platelet dual storage containers are used in the Intercept pathogen reducing equipment. These items are vital in the collection, treatment and sustainment of adequate inventory of blood platelets products for routine and emergent patient care and mission requirement. Pathogen reduction of donated blood platelet products reduces the transmission of viruses and infections upon transfusion. US Naval Hospital Okinawa PACOM Armed Services Blood Bank Center (ASBBC) is mandated by FDA to conduct pathogen reduction process for all collected blood platelets. Supplies of the platelet sets are historically sustained thru a drop shipment contract. The suggested vendor is the sole manufacturer and provider of the platelet sets.
Fenwal, Inc., is the only source capable of meeting the government’s minimum requirements.
Delivery Period: 1 October 2026 through 30 September 2027
Delivery Location: MAB, DLA TROOP SUPPORT XDOCK WEST PROJECT, C/O CARDINAL HEALTH MPS DISTRIBUTION CENTER, 4551 EAST PHILADELPHIA STREET, ONTARIO CA 91761
This notice of intent is not a request for competitive proposals, and no formal solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement. Submissions must include management, technical, and cost data in sufficient detail accompanied by convincing evidence to clearly demonstrate the capability to provide the required equipment and preventive maintenance. Capability statements shall not exceed four (4) pages (8.5" x 11" format) using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. Requests for documentation, inquiries for additional information, or submissions consisting solely of questions will not be considered affirmative responses. A determination by the Government not to compete this requirement based on responses to this notice is solely within the discretion of the Government. Information received will be considered exclusively for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole-source purchase order.
Response Instructions: If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to:
- Mariangela Monsalve at mariangela.j.monsalve.civ@health.mil
- Bobbie Dobberstein at bobbie.s.dobberstein.ctr@health.mil
The closing date for challenges is no later than 1000 Pacific Daylight Time, Friday, August 28, 2026.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
- 2739T ROOSEVELT DRIVE OFFICE 143, BUILDING H-201T
- CAMP PENDLETON , CA 92055
- USA
- Bobbie Dobberstein
- bobbie.s.dobberstein.ctr@health.mil
- Phone Number 4789194484
- Mariangela Monsalve
- mariangela.j.monsalve.civ@mail.mil
- Aug 13, 2026 10:11 am PDTSources Sought (Original)
See Also
Follow Dapagliflozin Tablets Active Contract Opportunity Notice ID SPE2D2-26-R-0018 Related Notice Department/Ind. Agency
DEPT OF DEFENSE
Follow Progesterone Capsules Active Contract Opportunity Notice ID SPE2D2-26-R-0015 Related Notice SPE2D2-26-R-0015 Department/Ind.
DEPT OF DEFENSE
Due by 9/18/2026
Follow 65--SURVIVAL KIT,INDIVIDUA Active Contract Opportunity Notice ID SPE2DS26T414R Related Notice Department/Ind. Agency
DEPT OF DEFENSE
Due by 9/15/2026
Follow 6505--Ticagrelor Tablets Active Contract Opportunity Notice ID 36E79726R0028 Related Notice 36E79726R0028 Department/Ind.
VETERANS AFFAIRS, DEPARTMENT OF
Due by 9/17/2026